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Abstract
Objective: Earlier studies have reported that a decrease in exercise capacity might indicate endothelial dysfunction. However, the effects 
of improvement of endothelial functions on exercise capacity have not been evaluated. The aim of the present study is to investigate the 
effects of nebivolol on flow-mediated dilatation (FMD), and on the exercise capacities of the patients with slow coronary flow (SCF).
Methods: The study population included 25 subjects with SCF (Group 1) documented by the thrombolysis in myocardial infarction 
(TIMI) frame count, and 25 control group (Group 2) subjects with normal coronary angiography, for a total of 50 subjects who underwent 
coronary angiography due to several indications and had no coronary lesion. The TIMI frame count (TFC) values of the subjects in 
Group I for left anterior descending artery, right coronary, and circumflex coronary artery were 61.8 ± 30.6, 37.2 ± 17.4, and 34.6 ± 17.4, 
respectively. All the subjects received nebivolol 5 mg/day.
Results: At the end of the first month of FMD, the mean exercise duration (MED) and the Duke Scores of the patients with SCF were 
significantly higher than the baseline values. However, the values by the sixth month did not differ from that at the first month. Although 
a numerical improvement compared to the baseline values was observed for the subjects in Group 2 by the measurements at the end of 
the first and the sixth month, this difference was not statistically significant.
Conclusions: Nebivolol treatment increases FMD in the subjects with SCF. The difference in the exercise parameters of these subjects 
is particularly dramatic, and such an outcome may indirectly indicate long-term improvement in endothelial function.
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Introduction
Slow coronary flow (SCF) phenomenon is a microvascular 
disease diagnosed by detection of slow passage of 
the contrast agent in the absence of epicardial occlu-
sive  disease.  In  1972,  Tambe  et  al  first  described 
the  SCF  phenomenon  in  six  patients  with  chest 
pain.1  It  is  known  that  in  patients  detected  with 
SCF,  flow-mediated  dilatation  (FMD)  is  signifi-
cantly  impaired  compared  to  the  patients  with 
normal  coronary  flow.  Consequently,  endothelial 
dysfunction plays an important role in the pathogen-
esis of SCF phenomenon.2 The benefit ratios of these 
patients  using  conventional  antianginal  drugs  are 
quite low. While it has been reported that the decrease 
in exercise capacity might indicate endothelial dys-
function, the effects of improvement of endothelial 
functions on exercise capacity were not evaluated. 
It is known that endothelial dysfunction is present in 
the patients who are detected with SCF.3 Nebivolol 
(Vasoxen 5 mg tablets), a third-generation beta-blocker 
agent,  may  improve  endothelial  functions  in  these 
patients.  Exhibiting  the  relationship  between  SCF 
progression and endothelial dysfunction is important.4 
Therefore, nebivolol, an agent that improves endothe-
lial dysfunction by inducing L-arginine/nitric oxide 
pathway-dependent vasodilatation, was used in the 
present study. The effects of nebivolol on FMD and 
exercise  capacities  of  the  patients  with  SCF  were 
investigated.
Methods
Patients who had undergone coronary angiography 
between October 2003 and May 2008 were screened, 
and 25 subjects with SCF detected by angiography 
were included in Group 1. The control group (Group 2) 
also included 25 subjects with normal coronary flow 
in the coronary angiography performed at the same 
period.  The  hospital  Ethics  Committee  approved 
the  study  protocol,  and  each  subject  signed  a 
written  informed  consent  prior  to  enrolment.  The 
demographic characteristics of the two groups were 
similar. No coronary lesion was present in any of the 
subjects.
SCF  was  defined  as  presence  of  thrombolysis 
in myocardial infarction (TIMI) Grade 2 flow in at 
least one of the coronary arteries angiographically 
with stenosis of less than 40% or without any lesion. 
The  diagnosis  was  made  by  two  independent  and 
experienced cardiologists and a cardiovascular surgeon. 
Excluded from the study were subjects with TIMI 
Grade 2 flow after a coronary intervention, left ven-
tricular ejection fraction of less than 50%, valvular 
insufficiency, conduction disorders of sinus and atrio-
ventricular  nodes,  known  peripheral  vascular  dis-
ease or diabetes mellitus, restrictive; hypertrophic or 
dilated  cardiomyopathy,  left  ventricular  hypertro-
phy; vasculitis and pulmonary renal or hematologic 
disease, and those who needed to receive additional 
medication.
The “TIMI frame count” method by Gibson et al 
was used to measure the opaque material and to detect 
the SCF pattern.5 The first frame was defined as the 
frame in which the opaque material entered coronary 
artery ostium and the coronary artery was reached, 
and the last frame was defined as the one needed for 
the  imaging  of  the  distal  landmark  by  the  opaque 
material. Distal landmarks were distal bifurcation for 
the left anterior descending artery (LAD), end of the 
distal bifurcation for the circumflex artery (Cx), and 
the first side branch of posterolateral artery (PLA) 
for the right coronary artery (RCA). The frame count 
of each artery was calculated by subtracting the first 
frame number from the last frame number. The TIMI 
frame count of LAD was significantly higher than the 
TIMI frame count of RCA and Cx, since the distance 
between the proximal and distal bifurcations of the 
LAD  was  longer  than  the  other  coronary  arteries. 
Taking account of the requirement for the standardiza-
tion of LAD frame (which is longer compared to other 
coronary arteries), Gibson attained a correction factor 
of 1.7 by dividing the TIMI frame count of LAD by 
the mean of combined frame count of Cx and RCA. 
The reference values (mean ± standard deviation) of 
the normal frame counts required for filling up coro-
nary arteries, corrected according to the length of cor-
onary artery, were 36 ± 1 for the LAD, 22.2 ± 4 for 
the Cx, and 20.4 ± 3 for the RCA. In the present study, 
in Standard 2 or above, mean values were used, while 
the values above 38 for the LAD, 30 for the Cx, and 
26 for the RCA were accepted as SCF.6–8
Twenty-five subjects with documented SCF defined 
according to the TIMI frame count method included 
13  females  and  12  males  with  a  mean  age  of 
56.1 ± 7.9 years. The mean frame count of the subjects 
in this group was found to be 61.8 ± 30.6 for the LAD, 
37.2 ± 17.4 for the RCA, and 34.6 ± 17.4 for the Cx.Nebivolol and slow coronary flow
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The control group consisted of  10 males and 15 
females. The mean age of the subjects was 52.1 ± 8.4 
years. The mean frame count of the subjects in the 
control group was calculated to be 31.4 ± 11.3 for 
the LAD, 22.6 ± 5.7 for the RCA, and 20.3 ± 7.1 for 
the Cx (Table 1).
The measurement of FMD and the exercise test were 
carried out for each of the subjects. In all the subjects, 
endothelial function was assessed by measuring FMD 
using ultrasonographic examination of the forearm. All 
the patients were instructed to abstain from alcohol and 
caffeine 12 h before the test. The test was performed 
at  appropriate  room  temperature  after  the  subjects 
had  fasted  for  10–12  h.  High  resolution  Doppler 
ultrasound (HDI-5000; ATL, Bothell, Washington) was 
used for the test. Following the measurement of base-
line brachial artery diameter, a sphygmomanometer 
cuff was placed 5 cm above the last measurement 
location and inflated to 220 mmHg. The air in the cuff 
was subsequently released after 5 min. The sudden 
increase of the flow caused by the release of the cuff-
induced FMD. FMD rates were determined 30s after 
the release of the cuff, and the third measurement 
was done after 15 min. Sublingual nitroglycerine was 
administered  to  evaluate  nitrate-induced  dilatation, 
and  measurements  were  performed  after  3–4  min. 
The  brachial  artery  diameter  was  measured  from 
the  anterior  to  the  posterior  interface  between  the 
media  and  the  adventitia,  and  determined  at  end-
diastole. An  average  of  three  mean  measurements 
from three cardiac cycles was used. Two independent 
researchers (a cardiologist and a radiologist) evaluated 
the measurements,9 Flow-mediated vasodilation was 
calculated as the percentage change in artery diameter 
from baseline to reactive hyperemia. Nitroglycerin-
mediated vasodilation was also calculated by the same 
technique.
All the subjects in Group 1 and 2 received nebivolol 
5 mg/day orally (Vasoxen 5 mg tb). FMD and the 
exercise test were repeated after one month and then 
six months later.
Results
FMD values obtained one month after the initiation 
of treatment with nebivolol, were significantly higher 
than the baseline values in the group of patients with 
SCF ( p  0.001). The MED increased from 5.9 ± 2.1 to 
8.3 ± 1.9, which was statistically significant ( p = 0.016). 
The Duke Score was also evaluated as statistically 
higher ( p  0.001) (Table 2).
No significant difference in any of the three param-
eters was observed during evaluation of the values 
Table 1. Demographic characteristics of the subjects.
Group 1 n = 25 Group 2 n = 25 p
Age (years) 56.1 ± 7.9 52.1 ± 8.4 ns
Male 12 (48%) 10 (40%) ns
Female 13 (52%) 15 (60%) ns
smoking 6 (24%) 5 (20%) ns
CoPD 1 (4%) 2 (8%) ns
BMi (kg/m2) 27.1 ± 0.9 26.2 ± 1.0 ns
systolic blood pressure (mmhg) 125 ± 5 126 ± 4 ns
Diastolic blood pressure (mmhg) 77 ± 3 76 ± 3 ns
heart rate (beat/min) 67 ± 4 68 ± 5 ns
hemoglobin (g/dL) 14.1 ± 1.2 14.3 ± 1.3 ns
LDL cholesterol (mg/dL) 121 ± 9 118 ± 7 ns
Frame count
  LAD 61.8 ± 30.6 31.4 ± 11.3 0.002
  CX 34.6 ± 17.4 22.6 ± 5.7 0.044
  rCA 37.2 ± 17.4 20.3 ± 7.1 0.001
Abbreviations: LAD, left anterior descending artery; CX, circumflex coronary artery; RCA, right coronary artery; BMI, body mass index. NS, not significant 
(p  0.05).Tiryakioglu et al
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obtained  at  the  first  and  six  months,  respectively 
(Table 2).
In terms of the baseline values of the control group 
(Group 2) and the study group (Group 1), the FMD 
was better in the control group (Group 2) (p  0.001) 
(Table 3).
Although  first  month  values  of  the  subjects  in 
Group 1 and Group 2 were higher compared to base-
line values, it was observed that despite the increase, 
the  FMD  in  Group  1  was  still  lower  than  that  in 
Group 2 (p = 0.001) (Table 4).
It  was  observed  that  all  the  three  parameters 
showed improvement in the sixth month. However, 
FMD in the study group was statistically lower com-
pared with the control group (Table 5).
Discussion
In earlier studies, it was reported that the decrease in 
exercise capacity might indicate endothelial dysfunction. 
However, the effects of the improvement of endothelial 
functions on exercise capacity were not evaluated.
Most patients with SCF have symptoms and signs 
of  clinical  coronary  artery  disease.  About  4%  of 
SCF patients are hospitalized due to unstable angina 
pectoris. An estimated 80% have recurrent anginal 
complaints, while 20% are again hospitalized due to 
angina pectoris.1,3,6
Although patients with normal coronary arteries 
who experience chest pain are generally thought to 
have  good  prognosis,7  it  is  believed  that  they  are 
not entirely safe owing to the continued presence of 
symptoms,8 and possibly acute coronary syndrome 
risk.2  Przybojewski  and  Becker  have  reported  that 
patients  with  SCF  might  experience  myocardial 
infarction, but it is not known whether this has any 
effect on increasing thrombosis.9 Atak et al reported 
that  QT  dispersion  associated  with  ventricular 
arthymia  risk  as  well  as  cardiovascular  mortality 
increased in patients with SCF.10
It is not known whether there will be an occur-
rence of thrombosis of the coronary artery among 
these patients in the future. However, fast coronary 
flow has several benefits, including improved quality 
of life and prevention of future complications.
Through the use of a non-invasive technique, we 
tried to assess whether the coronary flow increased 
or not. For this purpose, we used the brachial artery 
FMD technique, a test that is frequently used and 
commonly accepted.
Nebivolol is a novel, potent, and selective Beta-1 
adrenergic receptor inducing endothelium-dependent 
arterial and venous vasodilatation via L-arginine/nitric 
oxide pathway. Nebivolol reduces the blood pressure 
and  peripheral  vascular  resistance.  Furthermore, 
it  does  not  depress  the  functions  of  left  ventricle 
in  healthy  subjects  and  hypertensive  patients,  and 
may even achieve improvements. In earlier studies, 
nebivolol did not only improve the distensibility and 
compliance  of  great  arteries,  but  also  reduced  left 
ventricular hypertrophy in hypertensive patients.4
Table 2. Values in the study group during the first month and six months after starting nebivolol treatment.
study Group Baseline First month sixth month
FMD 0.0306 ± 0.01 0.0426 ± 0.01* 0.435 ± 0.01
MeD 5.9 ± 2.1 8.3 ± 1.9** 8.1 ± 2.0
DUKe score 1.3 ± 1.9 4.2 ± 1.6* 4.1 ± 1.7
Abbreviations: FMD, flow-mediated dilatation; MED, mean exercise duration.
notes: *p  0.001; **p = 0.016.
Table 3. The difference between the groups before the study.
Group 1 Group 2 p
FMD 0.0306 ± 0.01 0.0685 ± 0.02 0.001
MeD 5.9 ± 2.1 6.1 ± 2.2 ns
DUKe score 1.3 ± 1.9 2.1 ± 2.3 ns
Abbreviations:  FMD,  flow-mediated  dilatation;  MED,  mean  exercise 
duration. NS, Not significant (p  0.05).
Table 4. Comparison of the first month values of both groups.
First month Group 1 Group 2 p
FMD 0.0426 ± 0.01 0.0672 ± 0.01 0.001
MeD 8.3 ± 1.9 7.2 ± 1.7 ns
DUKe score 4.2 ± 1.6 3.9 ± 1.5 ns
Abbreviations:  FMD,  flow-mediated  dilatation;  MED,  mean  exercise 
duration. NS, Not significant (p  0.05).Nebivolol and slow coronary flow
Clinical Medicine: Cardiology 2009:3  119
publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Nebivolol treatment does not effect, but sometimes 
may  improve  exercise  tolerance.  In  hypertensive 
patients, one dose of nebivolol is effective for 24 h, 
with an absolute peak-trough ratio. The hypotensive 
effect  of  nebivolol  is  independent  of  age,  weight, 
smoking habits, alcohol consumption, and diabetes. 
Nebivolol treatment is effective in both young and 
old populations, and its antianginal efficacy prevents 
hemodynamic  deterioration  in  patients  with  stable 
congestive heart failure.1,4,11
The antiproliferative effects of nebivolol have been 
observed in endothelial and smooth muscle cell cultures. 
Infusion of nebivolol causes vasodilatation in all vas-
cular beds as a result of endothelium-dependent mecha-
nisms and the stimulation of Beta-3 adrenoreceptors,11 
In addition, Kurtoğlu et al have shown that SCF could 
become normal with dipyridamole treatment.12
Due to the benefits mentioned earlier, nebivolol 
was used in the patient group for whom endothelial 
dysfunction was considered. It was found that the FMD 
parameters of brachial artery, and more importantly, 
the  exercise  parameters,  improved  significantly  in 
patients with SCF.
In conclusion, nebivolol increases FMD in patients 
with SCF. The difference in the exercise parameters 
of these subjects is particularly dramatic, and such an 
outcome may indirectly indicate long-term improve-
ment in endothelial function.
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